Presence of protein marks toxicity in leukemia
the ONA take:
A recent study examined the protein inositol polyphosphate 4-phosphatase II (INPP4B) in patients that had been diagnosed with acute myeloid leukemia.
When examined, the data indicated that the presence of this protein indicates a likely toxicity effect associated with chemotherapy.
Chemotherapy is a standard clinic treatment for this disease, but patients can now be screened for inositol polyphosphate 4-phosphatase II and recommended for other treatments less likely to be toxic as needed.
The researchers hope to explore exactly how the protein behaves in cancer cells, specifically related to chemoresistance, so the protein and pathway may one day be effectively targeted.
This research was led by PhD student Sewa Rijal from the Faculty of Medicine, Nursing and Health Sciences (FMNHS), under the supervision of Professor Andrew Wei and Professor Christina Mitchell, Dean of FMNHS. Findings were published in the journal Blood.
Presence of this protein indicates a likely toxicity effect associated with chemotherapy.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|